Tag: Nacimbio

Joint Stock Company National Immunobiological Company was founded on 29 October, 2013 as a Holding Company (an integrated entity) within Rostec State Corporation to operate in the area of immunobiological products development and production.
The holding was established to secure independence on imports for Russia’s healthcare and medicinal products supply system through the development of domestic production and science expertise. Prioritized products are immunobiological preparations and medicinal preparations for the treatment of infectious diseases.
Nacimbio’s mission is to ensure national sovereignty in manufacture and supply of medicinal products, medical supply that are not manufactured domestically, as the absence of their production poses a threat to the national healthcare security.

Nacimbio completed Phase I clinical trials of the rotavirus vaccine

nacimbio
Nacimbio has completed the first phase of clinical trials of the rotavirus vaccine. The new drug will be packaged in Russia in 2020 already, while the full production cycle will be launched in 2026.

Nacimbio to provide extra 200 million units of blood products to Russian regions

plasma
Nacimbio concluded eight new contracts with the Ministry of Health of the Russian Federation for the supply of four units (INN) of blood plasma products.

Nacimbio expands R&D center for the development of substances

sintez
Increasing the production of medicines from its own substances is the medium term strategic goal of the Joint Stock Company Kurgan Society of Medical Preparations and Products Synthesis (part of Marathon Pharma and Nacimbio).

Russia completed development of a highly effective combined vaccine

microgen
Microgen completed development of combined vaccine against measles, rubella and mumps. Vactrivir will be the first Russian combined drug providing protection against three dangerous diseases.

Microgen developed live influenza vaccine for children in the form of spray

microgen
The new product of NPO Microgen, a subsidiary of Nacimbio pharmaceutical holding company (a part of Rostec Corporation), is the first Russian live influenza vaccine in liquid form that does not require intramuscular injections.

Nacimbio supplied more than 1 million doses of TBE vaccine

microgen
In January - May 2018, Nacimbio, a pharmaceutical holding company of Rostec Corporation, has supplied to all regions of Russia more than 1 million doses of vaccines for prevention of tick-borne encephalitis (TBE).

Nacimbio will supply blood products to Russian Ministry of Health

nacimbio
Nacimbio JSC, a pharmaceutical subsidiary of Rostec Corporation, signed four new contracts with the Russian Ministry of Health for 2018 supplies of blood-derived products under the Seven Nosologies program.

Nacimbio was designated as vaccines supplier for National Vaccination Schedule

nacimbio
Nacimbio JSC, a pharmaceutical holding company of Rostec Corporation, received the status of sole supplier of immunobiological medicines used for vaccinations under the National Vaccination Schedule.

Nacimbio will supply blood plasma product to Russian Ministry of Health

nacimbio
The Russian Ministry of Health will purchase a blood plasma product from Nacimbio, a subsidiary of Rostec Corporation, for more than 1 billion rubles following two auctions held by the Ministry for supply of this medicine.

Russian-made Relatox botulinum toxin helps to treat hyperhidrosis

relatox
NPO Microgen, a part of Nacimbio holding company, completed the clinical trials to expand the indications for use of Relatox, a botulinum toxin type A.

NPO Microgen launches a production area for botulinum toxins

microgen
NPO Microgen, a subsidiary of Nacimbio holding company of Rostec Corporation, is launching a new modern production area to manufacture Relatox, the only Russian botulinum toxin type A

Anton Katlinsky says that Russia cannot wait in a queue to get the vaccines

katlinskiy
Anton Katlinsky, the Advisor to the CEO of Nacimbio and the President of FORT, a biopharmaceutical company, discussed with other experts the scenarios for provision of vaccines to the Russian market

Nacimbio presents its key projects and new R&D

nacimbio
Nacimbio, a pharmaceutical holding company of Rostec Corporation, takes part in PharmMedProm-2017 exhibition held during the Russian Health Care Week

Nacimbio will invest 2.2 billion rubles in vaccine manufacturing

Fort
The Governor of the Ryazan region and the President of FORT LLC have signed an agreement to extend the provision of state support

Vaccination will become a driver of economic growth in the 21st century

vaccines
Nikolai Briko, Doctor of Medical Sciences and Member of the Scientific and Technical Council of Nacimbio, said that this century is the age of vaccines

Nacimbio completes trials of pentavaccine with acellular pertussis component

research
National Immunobiological Company (Nacimbio) completed the clinical trials of the first Russian combined 5-component vaccine with acellular pertussis component